Latest Breaking News On - Alimera science - Page 1 : comparemela.com

Q3 2024 EPS Estimates for Alimera Sciences, Inc (NASDAQ:ALIM) Decreased by Analyst

Alimera Sciences, Inc. (NASDAQ:ALIM – Free Report) – HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Alimera Sciences in a report issued on Thursday, May 16th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their prior forecast […]

United statesAlimera sciencesStonepine capital managementHedge funds weigh in on alimera sciencesNews ratings for alimera sciences dailyMaxim groupWorth venture partnersAlimera sciences stock performanceVanguard group incCapital managementAlimera sciences incFree reportAlimera scienceGet free reportVenture partnersLane capital

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

While it may not be enough for some shareholders, we think it is good to see the Alimera Sciences, Inc. ( NASDAQ:ALIM.

Alimera sciencesAlimera scienceShare priceRevenue increase

Diabetic Retinopathy Market to Witness the Highest Growth in Coming Years 2023-2030: Novartis AG, Regeneron Pharmaceuticals, Bayer Healthcare, Actavis Plc, Pfizer Inc |

Diabetic Retinopathy Market to Witness the Highest Growth in Coming Years 2023-2030: Novartis AG, Regeneron Pharmaceuticals, Bayer Healthcare, Actavis Plc, Pfizer Inc |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAsia pacificBoehringer ingelheimPfizer incRegeneron pharmaceuticalsAbbott laboratories ltdCoherent market insights pvt ltdRoche ltdActavis plcTherapeutics incSample copyDiabetic retinopathy marketRetinopathy marketCompetitive outlooksBayer healthcare

Summit Therapeutics (NASDAQ:SMMT) versus Alimera Sciences (NASDAQ:ALIM) Financial Survey

Summit Therapeutics (NASDAQ:SMMT) versus Alimera Sciences (NASDAQ:ALIM) Financial Survey
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSummit therapeutics incAlimera sciences incAkeso incAlimera sciencesEyepoint pharmaceuticals us incSummit therapeuticsGet free reportAlimera scienceGiven alimera scienceTherapeutics incOperating costEyepoint pharmaceuticalsSummit therapeutics daily

Karyopharm Therapeutics (NASDAQ:KPTI) & Alimera Sciences (NASDAQ:ALIM) Critical Survey

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) and Alimera Sciences (NASDAQ:ALIM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Valuation and Earnings This table compares Karyopharm Therapeutics and […]

United statesSelective inhibitor of nuclear exportAlimera sciencesTherapeutics incAntengene therapeuticsMenarini groupEyepoint pharmaceuticals us incKaryopharm therapeutics incAlimera sciences incKaryopharm therapeuticsGet ratingAlimera scienceGiven karyopharm therapeuticSelective inhibitorNuclear exportMyelodysplastic neoplasms